Inicio>>Signaling Pathways>> Chromatin/Epigenetics>> Histone Acetyltransferases>>GNE-207

GNE-207

Catalog No.GC33212

GNE-207 es un inhibidor potente, selectivo y biodisponible por vÍa oral del bromodominio de CBP, con un IC50 de 1 nM, exhibe un Índice selectivo de> 2500 veces contra BRD4 (1). GNE-207 muestra una excelente potencia CBP, con un EC50 de 18 nM para la expresiÓn de MYC en células MV-4-11.

Products are for research use only. Not for human use. We do not sell to patients.

GNE-207 Chemical Structure

Cas No.: 2158266-58-9

Tamaño Precio Disponibilidad Cantidad
250mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com


Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

GNE-207 is a potent, selective and orally bioavailable inhibitor of the bromodomain of CBP, with an IC50 of 1 nM, a selectively index of?>2500-fold against BRD4 (1) (IC50, 3.1 μM)[1]. GNE-207 shows excellent CBP potency, with an EC50 of 18 nM for MYC expression in MV-4-11 cells[1].

GNE-207 is a potent, selective and orally bioavailable inhibitor of the bromodomain of CBP, with an IC50 of 1 nM, a selectively index of?>2500-fold against BRD4 (1) (IC50, 3.1 μM)[1].GNE-207 shows excellent CBP potency, with an EC50 of 18 nM for MYC expression in MV-4-11 cells[1].

GNE-207 (5mg/kg) shows moderate clearance in PK, with acceptable oral bioavailability[1].

[1]. Lai KW, et al. Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300. ioorg Med Chem Lett. 2018 Jan 1;28(1):15-23.

Reseñas

Review for GNE-207

Average Rating: 5 ★★★★★ (Based on Reviews and 22 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for GNE-207

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.